

PTO/SB/07 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCEUnder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on November 18, 2003
Date



Signature

Mark Chao Reg. No. 37,293

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify
each submitted paper.

Supplemental Amend. A and Response under 37 CFR 1.111
14 Pages total, including this page.

Application Ser. No. 10/018,962 Atty Dkt. No. 2618US0P
Filed 12/18/2001

ATTN: Group 1624
Examiner Richard Raymond

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
Washington, DC 20231.



RECEIVED
CENTRAL FAX CENTER

NOV 17 2003

TO: COMMISSIONER FOR PATENTS
ATTN: Group 1624/Examiner Richard Raymond
FAX: 1-703-872-9306
PHONE:
RE: 2618 USOP - Application. No. 10/018,962

FROM: Mark Chao, PhD, JD
DATE: November 17, 2003
PAGES: 15 including cover sheet
CC:

OFFICIAL

FAX MESSAGE:

Please find attached Supplemental Amendment "A" and Response under 37 CFR 1.111.

TAKEDA PHARMACEUTICALS NORTH AMERICA, INC.
475 Half Day Road Lincolnshire, Illinois 60069 Phone: 847-383-3000

Please contact the sender if all pages are not received. NOTICE: This transmittal is strictly intended for delivery only to the person listed above. This facsimile transmission may contain confidential or otherwise privileged information which is subject to Attorney-Client and/or Attorney Work Product Privilege, the disclosure of which is strictly prohibited. If you have received this facsimile by mistake please contact the sender immediately, at the phone number listed above (collect call) for instructions as to the return or disposal of this transmission.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

NOV 17 2003

OFFICIAL

Application No.:	10/018,962	Art Unit:	1624
Filed:	12/18/2001	Examiner:	Richard Raymond
1 st Inventor:	ITOH, Fumio.	Allowed:	
For:	Acylhydrazine Derivatives, Their Production and Use	Batch:	
Atty. Dkt. No.	2618 USOP	Paper No.:	

SUPPLEMENTAL AMENDMENT "A"
and RESPONSE under 37 CFR 1.111

Via Facsimile to 1-703-872-9306

Commissioner for Patents
 P.O. Box 1450
 Arlington, VA 22313-1450
 Sir:

In response to the Office Action mailed June 12, 2003 (Paper No. 9), Applicants respectfully request reconsideration of the claims in view of the substitute amendment and remarks set forth below. Please disregard the previously submitted amendments of OCT 14, 2003, as inadvertent errors were made in the chemical structures that were not the intended amendment.

The USPTO has authorization to charge any appropriate fee to our USPTO deposit account as provided.

AMENDMENT

In the Specification

Please make the following amendments in the specification as follows:

Please cancel the previously requested amendment on Page 29, by keeping "benzindazolyl" as originally filed.